"Ecnoglutide outperformed placebo in trials, showcasing its potential as a leading obesity treatment with significant weight loss results."
"In a phase 3 trial, individuals receiving ecnoglutide lost up to 13.8 kilograms while those on placebo lost only 200 grams."
"Ecnoglutide, a GLP-1 receptor agonist, effectively regulates appetite and blood sugar, distinguishing itself from traditional drugs like semaglutide."
"The treatment's ability to help maintain weight loss after cessation, with only a 1% regain, marks a significant advancement in obesity management."
Ecnoglutide, a glucagon-like peptide-1 analog developed by Chinese firm Sciwind Biosciences, shows remarkable weight loss results in clinical trials, with participants losing up to 13.8 kg. Results from a phase 3 study published in The Lancet Diabetes and Endocrinology reveal that 92.8% of individuals on the highest dose achieved over 5% body weight loss, which far surpasses the placebo group's performance. Beyond weight loss, ecnoglutide also effectively improves cardiovascular and diabetes risk factors, making it a promising innovation in obesity treatment.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]